Gina Walker of Chillicothe, Ohio, USA, is the proud mom of two very active kids. When she needed a blood transfusion following a medical emergency, she could feel confident in the safety of the procedure thanks to Abbott’s PRISMaEXT blood-screening system.
The blood donation that helped Gina was just one of millions screened every year by an Abbott system. We’ve been helping to protect the safety of the blood supply for more than 40 years, with systems like the ABBOTT PRISMnEXT, designed to enhance blood screening through automation and improved data management. Our blood transfusion instruments are used to screen the majority of the world’s blood supply.

It’s advancements like these that have helped Abbott maintain our position as a pioneer and leader in in vitro diagnostics. With a varied portfolio of sophisticated instruments, tests and technologies for screening and diagnosing diseases and monitoring general health, we help clinicians find and treat diseases earlier so patients can benefit from more-targeted treatment options.

As cost pressures and increased patient volumes put pressure on labs and the healthcare system, our high-volume platforms are developed to meet the lab’s most pressing needs for speed, accuracy and efficiency.

We also have a leading point-of-care testing platform, a growing line of best-in-class molecular instruments and tests, and we’re helping ensure the long-term success of our business with continued investment in our new-product pipeline. We expect to launch several new platforms in the coming years, offering more cost-effective, more efficient systems that promise to improve the performance of the healthcare system while also improving care.
Abbott is a global leader in in vitro diagnostics, offering a broad portfolio spanning immunoassay, clinical chemistry, hematology, blood screening, molecular, point of care and informatics. Our diagnostics solutions are designed to improve decision-making and patient care across the entire healthcare system. Abbott develops and commercializes in vitro diagnostics instruments, tests and related automation and informatics solutions for use in hospitals, reference labs, physician offices, emergency departments, critical care and remote settings.

Abbott’s focus on combining speed, accuracy and efficiency helps maintain our position as the world leader in immunoassay and blood screening.

2015 BUSINESS HIGHLIGHTS

- Acquired Omnilab, expanding lab informatics capabilities
- Announced a collaboration with Sekisui to offer coagulation testing solutions
- In February 2016, announced our intention to become the world leader in point-of-care testing by acquiring Alere Inc.
- Launched i-STAT Total ß-hCG test, allowing faster detection of early pregnancy in emergency situations
- Launched global campaign to inspire young people to become life-long blood donors
- Abbott scientists helped discover a previously unknown virus that may be linked to hepatitis C
Abbott is a leader in Point of Care Diagnostics

Abbott’s m2000 RealTime System provides automation, a broad assay menu, and other solutions to make laboratories more efficient

LEADING BRANDS ACROSS OUR DIAGNOSTICS BUSINESS

» ARCHITECT
  Immunoassay and clinical chemistry systems and tests

» ABBOTT PRISM
  Blood-screening system and reagents

» ACCELERATOR A3600
  Advanced lab-automation system

» CELL-DYN
  Hematology analyzers and reagents

» M2000
  Molecular system and tests for infectious diseases

» IRIDICA
  Breakthrough pathogen-identification system

» I-STAT
  Point-of-Care testing system and tests

These new Abbott systems will improve care while creating greater efficiencies in the healthcare system